{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:00:28Z","timestamp":1787587228099,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CHRU de Brest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Patients diagnosed with head and neck squamous cell carcinoma (HNSCC) face a significant risk of locoregional recurrence within the first two years after treatment. While early detection of recurrence could potentially improve patient outcomes, the impact of such detection on survival remains uncertain. The aim was to assess the potential benefit of a systematic post-treatment follow-up strategy using 18\u00a0F-FDG PET\/CT imaging on overall survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this multicenter case-control study, patients were treated in two health areas from two different regions in France. All adults diagnosed with histologically confirmed HNSCC and treated between January 2017 and December 2020 with curative intent, with a complete response on imaging were included in the study. Primary endpoint was 3-year overall survival. The log-rank test was used to compare 3-year OS rates between the CFU (conventional follow-up) and PET\/CT groups. A Cox regression model was used to assess the effect of the addition of 18\u00a0F-FDG PET\/CT on survival outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 697 patients were included (534 males [77%], median age[IQR] 62[57\u201369] years); 508 patients had CFU and 189 patients had CFU\u2009+\u2009systematic annual 18\u00a0F-FDG PET\/CT. Cox regression analysis showed a protective effect (OR\u2009=\u20090.56, 95%CI:0.397\u20130.795, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) of systematic 18\u00a0F-FDG PET\/CT. The 3-year OS in the PET\/CT group was better than in the CFU group (83.5\u2009\u00b1\u20092.8% vs. 73.4\u2009\u00b1\u20092.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.008). The analysis based on stage showed a significantly better 3-year OS for advanced stage III\/IV in the PET\/CT group (<jats:italic>n<\/jats:italic>\u2009=\u2009124) than in the CFU group (<jats:italic>n<\/jats:italic>\u2009=\u2009312)(79.9\u2009\u00b1\u20093.7% vs. 71.5\u2009\u00b1\u20092.7%, <jats:italic>p<\/jats:italic>\u2009=\u20090.045) as well as for early stage I\/II (90.5\u2009\u00b1\u20093.7% vs. 76.3\u2009\u00b1\u20093.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.047).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In this multicenter study, the use of 18\u00a0F-FDG PET\/CT as an alternative to annual chest CT in the follow-up of head and neck squamous cell carcinoma (HNSCC) is associated to a survival benefit at 3 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable (retrospective study).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07147-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T03:05:26Z","timestamp":1740539126000},"page":"2761-2770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["3-year overall survival benefit of systematic follow-up with 18F-FDG PET\/CT in asymptomatic patients treated for head and neck squamous cell carcinoma: a multicenter study"],"prefix":"10.1007","volume":"52","author":[{"given":"C.","family":"Mah\u00e9o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Abgral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Espitalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Le Pennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Le Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Eug\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marianowski-","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Y.","family":"Sala\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-9575","authenticated-orcid":false,"given":"Jean-Christophe","family":"Lecl\u00e8re-","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"7147_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"7147_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7147_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer incidence, mortality, years of Life Lost, Years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of Disease Study. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol"},{"key":"7147_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3174\/ajnr.A6614","volume":"41","author":"A Gore","year":"2020","unstructured":"Gore A, Baugnon K, Beitler J, Saba NF, Patel MR, Wu X, et al. Posttreatment Imaging in patients with Head and Neck Cancer without Clinical evidence of recurrence: should Surveillance Imaging extend beyond 6 months? AJNR Am J Neuroradiol. 2020;41:1238\u201344.","journal-title":"AJNR Am J Neuroradiol"},{"key":"7147_CR5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0003-438X(06)76673-7","volume":"123","author":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oto-Rhino-Laryn","year":"2006","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oto-Rhino-Laryngologie et de Chirurgie de la Face et du Cou. Post-therapeutic follow-up in upper airway squamous-cell carcinoma. Ann Otolaryngol Chir Cervicofac. 2006;123:240\u201379.","journal-title":"Ann Otolaryngol Chir Cervicofac"},{"key":"7147_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck cancers, Version 2.2020, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:873\u201398.","journal-title":"J Natl Compr Canc Netw"},{"key":"7147_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0720-048X(99)00120-5","volume":"33","author":"M Lell","year":"2000","unstructured":"Lell M, Baum U, Greess H, N\u00f6mayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol. 2000;33:239\u201347.","journal-title":"Eur J Radiol"},{"key":"7147_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bulcan.2019.01.002","volume":"106","author":"P-Y Sala\u00fcn","year":"2019","unstructured":"Sala\u00fcn P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. [Update of the recommendations of good clinical practice for the use of PET in oncology]. Bull Cancer. 2019;106:262\u201374.","journal-title":"Bull Cancer"},{"key":"7147_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","volume":"47","author":"P-Y Sala\u00fcn","year":"2020","unstructured":"Sala\u00fcn P-Y, Abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET\/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47:28\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7147_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/hed.10310","volume":"25","author":"LY Wong","year":"2003","unstructured":"Wong LY, Wei WI, Lam LK, Yuen APW. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25:953\u20139.","journal-title":"Head Neck"},{"key":"7147_CR11","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1002\/cncr.24595","volume":"115","author":"ME Zafereo","year":"2009","unstructured":"Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115:5723\u201333.","journal-title":"Cancer"},{"key":"7147_CR12","doi-asserted-by":"publisher","first-page":"e212915","DOI":"10.1148\/radiol.212915","volume":"307","author":"Y Anzai","year":"2023","unstructured":"Anzai Y, Chang C-P, Rowe K, Snyder J, Deshmukh V, Newman M, et al. Surveillance imaging with PET\/CT and CT and\/or MRI for Head and Neck Cancer and Mortality: a Population-based study. Radiology. 2023;307:e212915.","journal-title":"Radiology"},{"key":"7147_CR13","doi-asserted-by":"publisher","first-page":"e2326654","DOI":"10.1001\/jamanetworkopen.2023.26654","volume":"6","author":"J-C Lecl\u00e8re","year":"2023","unstructured":"Lecl\u00e8re J-C, Cl\u00e9ment C, Le Pennec R, Maheo C, Gujral DM, Schick U, et al. An intensive 18F-Fludeoxyglucose-Positron Emission Tomography with computed tomography-based strategy of Follow-Up in patients treated for Head and Neck squamous cell Carcinoma who are clinically asymptomatic. JAMA Netw Open. 2023;6:e2326654.","journal-title":"JAMA Netw Open"},{"key":"7147_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67:93\u20139.","journal-title":"CA Cancer J Clin"},{"key":"7147_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7147_CR16","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cncr.27892","volume":"119","author":"AS Ho","year":"2013","unstructured":"Ho AS, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, et al. Impact of positron emission tomography\/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013;119:1349\u201356.","journal-title":"Cancer"},{"key":"7147_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2214\/AJR.14.14166","volume":"205","author":"S Sheikhbahaei","year":"2015","unstructured":"Sheikhbahaei S, Taghipour M, Ahmad R, Fakhry C, Kiess AP, Chung CH, et al. Diagnostic Accuracy of Follow-Up FDG PET or PET\/CT in patients with Head and Neck Cancer after definitive treatment: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2015;205:629\u201339.","journal-title":"AJR Am J Roentgenol"},{"key":"7147_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/lary.23941","volume":"123","author":"KA Dunsky","year":"2013","unstructured":"Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope. 2013;123:2161\u20134.","journal-title":"Laryngoscope"},{"key":"7147_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0895-4356(95)00042-9","volume":"49","author":"F Barbone","year":"1996","unstructured":"Barbone F, Franceschi S, Talamini R, Barzan L, Franchin G, Favero A, et al. A follow-up study of determinants of second tumor and metastasis among subjects with cancer of the oral cavity, pharynx, and larynx. J Clin Epidemiol. 1996;49:367\u201372.","journal-title":"J Clin Epidemiol"},{"key":"7147_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s10654-018-0409-5","volume":"33","author":"E Leoncini","year":"2018","unstructured":"Leoncini E, Vukovic V, Cadoni G, Giraldi L, Pastorino R, Arzani D, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. Eur J Epidemiol. 2018;33:1205\u201318.","journal-title":"Eur J Epidemiol"},{"key":"7147_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/(SICI)1097-0347(199905)21:3<204::AID-HED4>3.0.CO;2-7","volume":"21","author":"X Le\u00f3n","year":"1999","unstructured":"Le\u00f3n X, Quer M, Diez S, Or\u00fas C, L\u00f3pez-Pousa A, Burgu\u00e9s J. Second neoplasm in patients with head and neck cancer. Head Neck. 1999;21:204\u201310.","journal-title":"Head Neck"},{"key":"7147_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ecc.12084","volume":"23","author":"W-S Liu","year":"2014","unstructured":"Liu W-S, Chang Y-J, Lin C-L, Liang J-A, Sung F-C, Hwang I-M, et al. Secondary primary cancer in patients with head and neck carcinoma: the differences among hypopharyngeal, laryngeal, and other sites of head and neck cancer. Eur J Cancer Care (Engl). 2014;23:36\u201342.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"7147_CR23","doi-asserted-by":"publisher","first-page":"e13255","DOI":"10.1111\/ecc.13255","volume":"29","author":"I Hoxhaj","year":"2020","unstructured":"Hoxhaj I, Hysaj O, Vukovic V, Leoncini E, Amore R, Pastorino R, et al. Occurrence of metachronous second primary cancer in head and neck cancer survivors: a systematic review and meta-analysis of the literature. Eur J Cancer Care (Engl). 2020;29:e13255.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"7147_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.oraloncology.2008.05.024","volume":"45","author":"CA Krabbe","year":"2009","unstructured":"Krabbe CA, Pruim J, van der Laan BFAM, R\u00f6diger LA, Roodenburg JLN. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol. 2009;45:234\u201340.","journal-title":"Oral Oncol"},{"key":"7147_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2967\/jnumed.108.055806","volume":"50","author":"R Abgral","year":"2009","unstructured":"Abgral R, Querellou S, Potard G, Roux P-YL, Duc-Pennec AL, Marianovski R, et al. Does 18F-FDG PET\/CT improve the detection of Posttreatment recurrence of Head and Neck Squamous Cell Carcinoma in patients negative for Disease on Clinical Follow-up? J Nucl Med. 2009;50:24\u20139.","journal-title":"J Nucl Med"},{"key":"7147_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00259-014-2889-1","volume":"42","author":"P Robin","year":"2015","unstructured":"Robin P, Abgral R, Valette G, Le Roux P-Y, Keromnes N, Rousset J, et al. Diagnostic performance of FDG PET\/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. Eur J Nucl Med Mol Imaging. 2015;42:72\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7147_CR27","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2021.39.15_suppl.4032","volume":"39","author":"JA Elliott","year":"2021","unstructured":"Elliott JA, Markar S, Klevebro F, Johar A, Goense L, Lowery MA, et al. ENSURE: an international multicenter study exploring whether surveillance after esophageal cancer surgery impacts oncological and quality-of-life outcomes. JCO. 2021;39:4032\u20134032.","journal-title":"JCO"},{"key":"7147_CR28","doi-asserted-by":"publisher","first-page":"e2342825","DOI":"10.1001\/jamanetworkopen.2023.42825","volume":"6","author":"AM Chen","year":"2023","unstructured":"Chen AM, Harris JP, Gan M, Nabar R, Tjoa T, Haidar YM, et al. Posttreatment Surveillance Imaging after Radiation for Head and Neck Cancer. JAMA Netw Open. 2023;6:e2342825.","journal-title":"JAMA Netw Open"},{"key":"7147_CR29","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.2967\/jnumed.109.065300","volume":"50","author":"CA Krabbe","year":"2009","unstructured":"Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009;50:1940\u20137.","journal-title":"J Nucl Med"},{"key":"7147_CR30","doi-asserted-by":"publisher","first-page":"8676787","DOI":"10.1155\/2022\/8676787","volume":"2022","author":"S Murtoj\u00e4rvi","year":"2022","unstructured":"Murtoj\u00e4rvi S, Malaspina S, Kinnunen I, Tuokkola T, Honka M-J, Saunavaara V, et al. Diagnostic accuracy of 18F-FDG-PET\/CT and 18F-FDG-PET\/MRI in detecting Locoregional recurrence of HNSCC 12 weeks after the end of Chemoradiotherapy: single-center experience with PET\/MRI. Contrast Media Mol Imaging. 2022;2022:8676787.","journal-title":"Contrast Media Mol Imaging"},{"key":"7147_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13244-022-01261-0","volume":"13","author":"E Katirtzidou","year":"2022","unstructured":"Katirtzidou E, Rager O, Varoquaux AD, Poncet A, Lenoir V, Dulguerov N, et al. Detection of distant metastases and distant second primary cancers in head and neck squamous cell carcinoma: comparison of [18F]FDG PET\/MRI and [18F]FDG PET\/CT. Insights Imaging. 2022;13:121.","journal-title":"Insights Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07147-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:22:52Z","timestamp":1749705772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7147"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07147-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Name of the Approval Committee: Brest Hospital ethics committee, Number of approval: 29BRC22.0040.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate declarations"}},{"value":"Consent to use of their data for each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No Competing Interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}